PDAC Proteomics After Neoadjuvant Therapy
Shotgun Proteomics, Proteomic characterization of the residual PDAC tumor mass after neoadjuvant chemo or combined chemo-radiation therapy
- 27/10/2023
- 79 samples
- DAC: EGAC00001002949
- Technology: Qexactive Plus
Access to proteomic (DIA) profiling of human pancreatic ductal adenocarcinoma after neoadjuvant chemo or chemo-radiation therapy
The recipient of files agrees to fully consent to the Data Access Agreement (DAA) provided by the Institute for Surgical Pathology for data access of the Proteomics’ colorectal and liver metastasis files, which is based on the harmonized DAA as provided by the EGA.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| Other |